PANC (PANC) Stock Price & Analysis
PANC (PANC) rose 0.00% to USD 0 as of June 10, 2026 at 03:37 UTC, according to Nexqual real-time market data.
PANC last closed at USD 0; the session ranged USD 0–0 on volume of 200 shares. Market capitalization is $321,841, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 03:37 UTC.
Key Statistics (as of June 10, 2026 at 03:37 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 200 shares |
| Market Cap | $321,841 |
| Exchange | PNK |
Technical Analysis (PANC)
Nexqual's technical model rates PANC "STRONG SELL" based on 0 bullish and 6 bearish signals across 124 daily candles, as of June 10, 2026 at 03:37 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (PANC)
Wall Street analysts rate PANC "None", per Nexqual as of June 10, 2026 at 03:37 UTC.
| Consensus Rating | None |
|---|
Earnings (PANC)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2008-09-30 | USD -0.15 vs est -0.2 ▲ beat |
| 2008-06-30 | USD -0.18 vs est -0.18 ▲ beat |
| 2008-03-31 | USD -0.16 vs est -0.19 ▲ beat |
| 2007-12-31 | USD -0.17 vs est -0.2 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Financials & Fundamentals (PANC)
| Total Revenue | $99,000 |
|---|---|
| Revenue Growth (YoY) | -20.00% |
| Gross Margin | +100.00% |
| Operating Margin | -31545.83% |
| Profit Margin | +0.00% |
| ROE | -168.83% |
| Debt / Equity | 345.33 |
| Current Ratio | 2.15 |
| Total Cash | $26.89M |
| Total Debt | $18.21M |
| Free Cash Flow | $-16.93M |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Financial Health Score (PANC)
Nexqual rates PANC's overall financial health "Critical" across five dimensions, as of June 10, 2026 at 03:37 UTC.
| Growth | Critical — Revenue -37% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $27M cash vs $18M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$17M, burning cash |
| Efficiency | Critical — ROE -169%, ROA -52.6% |
Ownership (PANC)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 0 |
| Short % of Float | +0.20% |
Source: Nexqual, June 10, 2026 at 03:37 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTII | NEUROBIOLOGICAL TECHNOLOGIES IN | USD 0 | ▲ 0% |
| OSCI | Osceola Gold, Inc. | USD 0.1 | ▲ 0% |
| PARD | PONIARD PHARMACEUT | USD 0 | ▲ 0% |
| GNTA | Genenta Science S.p.A. | USD 1.6 | ▼ 21.57% |
| ACUS | ACUSPHERE INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:37 UTC. This page is informational and not investment advice.